NCT01007383

LEO 27847 - A Study in Healthy Male Subjects

LEO 27847 - A Phase 1, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this first-in-man trial is to determine the safety and tolerability of ascending single and multiple doses of LEO 27847 in healthy male subjects. The trial will be performed in two parts. In Part 1, single doses of LEO 27847 will be administered to healthy male subjects. In Part 2, multiple doses of LEO 27847 will be administered to healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LEO 27847	First in man

Timeline

• Start date: 2009-09-01
• Primary completion: 2010-03-01
• Completion: 2010-04-01
• First posted: 2009-11-04
• Last updated: 2025-02-24

Locations

1 site across 1 country: United Kingdom